Allogene Therapeutics Reports $42.7 Million Net Loss in Q2 2026, Improved Financial Metrics

Allogene Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $42.7 million, a decrease from the $50.9 million loss recorded in the same period of 2025. For the first half of 2026, the company reported a net loss of $85.3 million, down from $110.7 million in the prior year. The reduction in losses is attributed to a significant decrease in operating expenses, which totaled $51.6 million for the quarter, compared to $56.8 million in the previous year, marking a 9% decline. The company generated $4.6 million in collaboration revenue during the quarter, a new revenue stream compared to the previous year when no such revenue was reported.

In terms of operational metrics, Allogene's research and development expenses decreased by 23% to $30.7 million for the second quarter, primarily due to reduced development costs and personnel-related expenses following a workforce reduction implemented in 2025. General and administrative expenses increased by 46% to $20.8 million, largely driven by leadership transition costs and stock compensation expenses. The company’s accumulated deficit as of June 30, 2026, stood at $2.1 billion, reflecting its ongoing investment in clinical development.

Allogene's balance sheet showed total assets of $550.1 million as of June 30, 2026, up from $415.9 million at the end of 2025. This increase was primarily due to a rise in short-term investments, which grew to $294.0 million from $198.5 million. The company’s cash and cash equivalents decreased to $38.6 million from $51.7 million, while total liabilities decreased to $113.9 million from $123.4 million, indicating improved financial management.

Strategically, Allogene has made significant advancements in its clinical programs, particularly with its lead product candidate, cemacabtagene ansegedleucel (cema-cel), which is currently in a pivotal Phase 2 trial for large B-cell lymphoma. The company has expanded its clinical trial sites internationally and received Fast Track designation from the FDA for cema-cel. Additionally, Allogene has initiated a new trial for ALLO-316, targeting advanced renal cell carcinoma, and is progressing with ALLO-329 for autoimmune diseases. The company anticipates that its current cash reserves, bolstered by recent public offerings, will support operations through at least the first quarter of 2029, although it expects to continue incurring losses as it advances its clinical programs.